Novo Nordisk A/s

Novo Nordiskals

Novo Nordish A/s

Uffe Bang Olsen

Knud Erik Andersen

Rolf Hohlweg

Tine Krogh Jo Slashedrgensen

Henrik Sune Andersen

Peter Madsen

Zdenek Polivka

Karel Sindelar

Alexandra Silhankova

Ursula Sonnewald

Hans Petersen

Frederik Christian Gro Slashednvald

Erik Fischer

Svend Treppendahl

Otylie Konigova

Martina Kovandova

Vladimir Valenta

Frantisek Miksik

Tine Krogh J&oslash;rgensen

Florenzio Zaragossa Dorwald

Silhankova Alexandra

Polivka Zdenek

Sindelar Karel

Kaler Sindelar

Florenzio Zaragossa D&ouml;rwald

Zden&eacute;k Polivka

Polivka Zden&eacute;k

Silh&aacute;nkov&aacute; Alexandra

Sindel&aacute;r Karel

Kjeld Madsen

Nils Langeland Johansen

Henning Tho Slashedgersen

Sidelar Karel

Tine Krough Jo Slashedrgensen

Mark Scheideler

Enud Erik Andersen

Tine Krogh Jo Slashedrgenen

Florenzio Zaragossa Do Slashedrwald

Tine Krogh Jorgensen

Tomas Kalisz

N-substituted azaheterocyclic carboxylic acids and their use

N-Substituted azaheterocyclic compounds

Heterocyclic compounds

The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

N-substituted azaheterocyclic carboxylic acids and esters thereof

The compounds are N-substituted azaheterocyclic compounds of formula I

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula

N-substituted azaheterocyclic compounds

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neuragenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Tricycle substituted with azaheterocyclic carboxylic acids

The present invention relates to novel N-substituted azaheterocyclic carboxylic acids andy esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.

Substituted dibenz[b,f]azepines and uses thereof

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, p, r and s are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to secretion and circulation of insulin antagonising peptides.

The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and m are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation, as well as their use for treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

The present invention relates to novel N-substituted azaheterocyclic compounds of the formula ##STR1## wherein X, Y, R.sup.1, R.sup.1a, R.sup.2, R.sup.2a, R.sup.12, R.sup.13, A, r and s are as defined in the detailed part of the present description, or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation. These compounds are also useful for treating indications caused by or related to the secretion and circulation of insulin antagonizing peptides, e.g., non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Growing community of inventors

Vallensb.ae butted.k, Denmark

Uffe Bang Olsen